Evidence map›Paper›PMID 36365244›Full record

ArticlePharmaceutics2022

Enabling In Vivo Optical Imaging of an Osmium Photosensitizer by Micellar Formulation.

Drashti Shah, Menitte Eroy, John Fakhry, Azophi Moffat, Kevin Fritz, Houston D Cole, Colin G Cameron, Sherri A McFarland, Girgis Obaid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Drashti ShahDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Menitte EroyDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
John FakhryDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Azophi MoffatDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Kevin FritzDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Houston D ColeDepartment of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, TX 76019, USA.ORCID 0000-0002-2922-2163
Colin G CameronDepartment of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, TX 76019, USA.ORCID 0000-0003-0978-0894
Sherri A McFarlandDepartment of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, TX 76019, USA.ORCID 0000-0002-8028-5055
Girgis ObaidDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.ORCID 0000-0002-9452-4467

Funding

Immunomodulating Ruthenium Metal Complexes for Melanoma PhotodynamicTherapyR01CA222227 · NCI · UNIVERSITY OF TEXAS ARLINGTON · PI GUJAR, SHASHI, MCFARLAND, SHERRI · 2018 to 2022
$2.6M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsR00CA215301 · NCI · UNIVERSITY OF TEXAS DALLAS · PI OBAID, GIRGIS · 2020 to 2022
$721k
NCI NIH HHS R00 CA215301NCI NIH HHS R01 CA222227NIH HHS R01CA222227
6 · The paper itself

Abstract

Osmium (Os)-based photosensitizers (PSs) exhibit unique broad, red-shifted absorption, favoring PDT activity at greater tissue depths. We recently reported on a potent Os(II) PS,

Indexed as

hypoxialuminescence imagingmicellar formulationosmium photosensitizersphosphorescence imagingphotodynamic therapy

Identifiers

PMID36365244
PMCPMC9693841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.